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Abstract 
We provide a survey of the disease entities 
associated with GATA1 mutations. 
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Genomic sequence 7,757 bases, mRNA six exons 
(five coding); Plus strand 
Figure 1. Alternative models for generation of GATA1 isoforms. The full GATA1 protein can only be translated from the full 
GATA1 mRNA, whereas the GATA1s protein can be translated either from the full gata-1mRNA or from the shorter splice variant 
in which exon 2 is skipped. 
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GATA1 is physiologically present as two protein 
isoforms that are derived from alternative splicing of 
the mRNA and the usage of an alternative translation 
initiation sites as shown in the Figure.  The full 
length GATA1 protein is comprised of 413 amino 
acids with a predicted molecular weight of 42.7 
KDa. The shorter form of the GATA1 protein 
(GATA1s) lacks the first 83 amino acid residues, 
which contains the so-called N-terminal activation 
domain (AD) (Gruber TA et al., 2015).  
Both proteins contain two Zinc finger domains 
mediating protein interactions and DNA binding. 
The expression level and ratio of both GATA1 
isoforms are thought to be important in directing the 
appropriate erythromegakaryocytic development. 
Expression 
Bone marrow: erythroid, megakaryocytic, mast cell 
and eosonophillic precursors.  




Transcription Factor, essential for erythroid and 
megakaryocytic development 
Homology 




Implicated dyserythropoietic anemia with 
thrombocytopenia/ Macrothrombocytopenia, and in 
Diamond-Blackfan anemia 
Somatic 
Myeloid proliferation associated with Down 
syndrome, including: 
- transient abnormal myelopoiesis associated with 
Down syndrome, and 
- myeloid leukemia associated with Down syndrome 
Implicated in 
Myeloid proliferation associated with 
Down syndrome, including transient 
abnormal myelopoiesis associated 
with Down Syndrome and myeloid 
leukemia associated with Down 
syndrome 
Acquired somatic mutations resulting in the 
exclusive production of the short-form GATA1 
protein (GATA1s) are pathognomonic in myeloid 
proliferation associated with Down syndrome (MP-
DS) (Ahmed M et al, 2004; Groet J et al, 2003; 
Rainis L et al, 2003; Wechsler J et al, 2002). These 
mutations are often in the forms of nonsense or 
frame-shift mutations that result in premature stop 
codons in exon 2 or 3, while sparing the alternative 
start codon further downstream in the exon 3. 
GATA1 mutations can be detected in umbilical cord 
blood of DS patients and in fetal liver of aborted DS 
embryos; therefore, these mutations are thought to 
occur in-utero, likely during fetal liver 
hematopoiesis (Ahmed M et al, 2004; Taub JW et al, 
2004).  The presence of GATA1s in the absence of 
full length GATA1 is thought to block 
megakaryocytic differentiation and promote the 
proliferation of megakaryoblasts (Vyas P et al, 1999; 
Li Z et al, 2005; Lee WY et al, 2018).  This disease 
entity only occurs in DS patients; however, the genes 
on chromosome 21 that enables the development of 
this disease are not known.  MP-DS mostly occurs in 
children with DS younger than 5 years of age and 
manifests initially as transient abnormal 
myelopoiesis (TAM) within 7 days of birth.  TAM is 
characterized by increased circulating 
megakaryocytic blasts, thrombocytopenia, and 
leukocytosis.  The majority of cases of TAM 
undergo clonal extinction and spontaneously remit. 
However, about a third of the cases eventually recur 
within 3 years as myeloid leukemia associated with 
Down syndrome (ML-DS), which phenotypically 
resembles acute megakaryocytic leukemia and 
requires therapy.  Next generation sequencing 
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studies comparing the genomic landscape of TAM 
and ML-DS have established the GATA1 mutations 
as the 'first-hit' mutations that presents 
phenotypically as TAM, and the subsequent gain of 
additional hits leads to the progression as ML-DS 
(Nikolaev SI et al, 2013; Yoshida K et al, 2013). 
Diamond-Blackfan anemia 
Diamond-Blackfan anemia (DBA) is a congenital 
condition characterized by isolated erythroid 
hypoplasia.  Approximately half of the DBA cases 
are associated with germline mutations that result in 
haploinsufficiency of ribosomal proteins.  A smaller 
subset of DBA cases, all of which are X-linked, is 
associated with germline GATA1 mutations, 
including substitution or splice site mutations 
involving exon 2 or 3 (Ludwig LS et al, 2014; 
Parrella S et al, 2014; Klar J et al, 2014; Sankaran 
VG, 2012).  These mutations, similar to those seen 
in MP-DS (see above), create missense or nonsense 
mutations at the first start codon or premature stop 
codons before the second alternative start codon, 
thereby precluding the production of the full length 
GATA1 and leading to the exclusive production of 
the short form of GATA1 (GATA1s).  Interestingly, 
several studies have suggested that in DBA with 
ribosomal protein haploinsufficiency exhibits 
altered translation of GATA1 mRNA, providing a 
possible converging mechanism of DBA (Ludwig 
LS et al, 2014; Khajuria RK et al, 2018). 
Dyserythropoietic anemia 
Dyserythropoietic anemia (DA), is a rare congenital 
red blood cell disorder characterized by anemia with 
erythrodysplasia (often abnormal forms with 
multinucleated nuclei) and varying degrees of 
macrothrombocytopenia with dysplastic 
megakaryocytes.  There are several isolated case 
reports describing the roles of GATA1 mutations in 
a subset of DA, which often presents as severe fetal 
anemia requiring intrauterine transfusion (Zucker J 
et al , 2016; Abdulhay NJ et al, 2019; Kratz CP et al, 
2008; Freson K et al, 2002; Nichols KE et al, 2000; 
Del Vecchio GC et al, 2005).  Based on the limited 
case reports, there appears to be two different classes 
of GATA1 mutations that can cause DA.  The first 
class of mutations (such as, V205M, G208R, and 
D218Y/G) appears to affect interaction with FOG-1 
(Friends of GATA1), a transcriptional co-factor 
required for normal erythroid and megakaryocytic 
differentiation.  The second class of mutations 
appears to affect the splicing of GATA1 transcripts 
that result in the preferential production of the short 
form of GATA1 protein, in a similar manner seen in 
DBA (see above).  Mutations altering the pattern of 
splicing were described to involve the 5' untranslated 
region and in the fifth intron.  Of note, these cases 
are distinctly different from congenital 
dyserythropoietic anemia type I, II, and III. Some 
have proposed to include the GATA1 mutated DA 
cases as congenital dyserythropoietic anemia 
variants. 
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